Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Seagen Inc.
KaliVir Immunotherapeutics
iOnctura
Sotio Biotech Inc.
Endeavor Biomedicines, Inc.
Novartis
Kezar Life Sciences, Inc.
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Incyte Corporation
University of Pittsburgh
Turnstone Biologics, Corp.
SOLTI Breast Cancer Research Group
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University of California, San Diego
Pfizer
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Rain Oncology Inc
University of Florida
Western Sydney Local Health District
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Infinity Pharmaceuticals, Inc.
Novartis
MacroGenics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Shenzhen BinDeBio Ltd.
Case Comprehensive Cancer Center
Novartis
University of Chicago
Mannkind Corporation